Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Ovid Therapeutic's purpose is to solve intractable medical problems.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.
Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.
Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.
2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.
Chroma Medicine is a biotechnology company that develops genetic medicines for the treatment of genetic disorders.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Via is a transport company that offers public mobility solutions for transit agencies, school districts, cities, and corporations.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Bambusa Therapeutics operates as biotechnology company.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Parse Biosciences is a biotechnology startup company that develops single-cell sequencing kit solutions for researchers.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Life Science. The firm invests across 21 different industry categories.
Among tracked funding rounds, Dianthus Therapeutics received $719.0M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $31.3B.
Janus Henderson Investors's average investment size is $160.4M across its portfolio of 227 companies.
Recent Janus Henderson Investors portfolio additions include Arbor Biotechnologies, Ovid Therapeutics, Curevo, Equillium, Longeveron. These companies were founded in 2020 or later.